|
Rimonyx Pharmaceuticals Ltd.
Core Business / Technology
Rimonyx Pharmaceuticals Ltd. is a development-stage biopharmaceutical
company with:
-A Unique Technology Platform, Focused on
the Discovery and Development of Innovative Drugs Targeted at
Glycosaminoglycan - Chemokine Interactions
-Pre-clinical Development Candidates for
Inflammatory Bowel Disease and Acute Pancreatitis
-A Pipeline of New Chemical Entities (NCEs),
Including Compounds for Rheumatoid Arthritis, Reperfusion Injury and
Multiple Sclerosis
Rimonyx’s proprietary SMIG (Small
Molecule Inhibitors of adhesion to Glycosaminoglycans) platform combines
an algorithm-selected collection of compounds, drug screening and
validated drug targets. Rimonyx’s business strategy involves both
developing an in-house pipeline of drug candidates and actively
out-licensing lead compounds to pharma companies. Rimonyx has an
experienced and talented management team who enlists the advice of
well-known scientists and experienced business advisors. The company is
located in close proximity to the Weizmann Institute of Science (Rehovot),
has currently a staff of five full-time employees and funds additional
personnel through an exclusive collaboration agreement. Rimonyx receives
funding from the Israeli Ministry of Industry and Trade and from private
investors.
Main Markets / Applications
Rimonyx is focusing on developing therapeutics for inflammatory and
autoimmune diseases.
Uniqueness / Advantage over Existing Products
Rimonyx’s strategy of targeting chemokine gradients has recently gained
momentum due to advantages over industry’s chemokine antagonist
programs.
Management
Dr. Paul Gregor, CEO
Prof. Regina Zhuk, Director, Discovery Research
Dr. Stanley Hirsch, Director & Business Advisor
Dr. Alan Lewis, Business Advisor
Seeking
Funding sources, strategic partners
Website
www.rimonyx.com
|
